TY  - BOOK
AU  - Sugarbaker, Paul H
TI  - Drugs, doses, and durations of intraperitoneal chemotherapy: standardizing HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma
SN  - 0265-6736
PY  - 2017///
KW  - IN PROCESS -- NOT YET INDEXED
KW  - Washington Cancer Institute
KW  - Journal Article
N2  - Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardization regarding the CRS, we are still lacking a much-needed standardization amongst the various IP chemotherapy treatment modalities used today in clinical practice. Pharmacologic evidence should be generated to answer important questions raised by the myriad of variables associated with IP chemotherapy
UR  - https://dx.doi.org/10.1080/02656736.2017.1291999
ER  -